Core Viewpoint - Korro Bio, Inc. is set to present at the 44th Annual J.P. Morgan Healthcare Conference, highlighting its focus on developing innovative genetic medicines through RNA editing [1]. Company Overview - Korro Bio is a biopharmaceutical company dedicated to creating a new class of genetic medicines aimed at treating both rare and common diseases [3]. - The company is developing a portfolio of programs that utilize the body's natural RNA editing process, allowing for precise and transient single base edits [3]. - By focusing on RNA editing rather than DNA, Korro aims to enhance the precision and tunability of genetic medicines, potentially leading to improved specificity and long-term tolerability [3]. - Korro plans to leverage its proprietary platform, established regulatory pathways, and manufacturing expertise to bring its oligonucleotide-based medicines to patients [3]. Investor Relations - Korro intends to use its Investor Relations website, LinkedIn, and X (Twitter) for disclosing material nonpublic information and fulfilling its disclosure obligations under Regulation FD [4]. - Investors are encouraged to monitor Korro's Investor Relations website and follow its social media channels for updates and information [4].

Core Insights - Korro Bio, Inc. is actively participating in several investor and scientific conferences throughout September 2025, showcasing its commitment to engaging with the investment community and sharing insights on its innovative approaches in genetic medicine [1][2][3][4][5][6]. Company Overview - Korro Bio is a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines that utilize RNA editing to address both rare and prevalent diseases. The company aims to harness the body's natural RNA editing process for precise and transient single base edits, which may enhance specificity and long-term tolerability compared to traditional DNA editing methods [7]. Upcoming Events - Key management members, including Dr. Ram Aiyar (CEO), Dr. Loic Vincent (CSO), and Vineet Agarwal (CFO), will participate in various investor meetings and presentations at notable conferences such as: - Citi's 2025 Biopharma Back to School Conference on September 3, 2025 [1] - Cantor Global Healthcare Conference on September 4, 2025 [2] - Wells Fargo Securities Healthcare Conference on September 5, 2025 [3] - H.C. Wainwright 27th Annual Global Investment Conference and Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025 [4][5] - RNA Leaders USA Congress on September 11, 2025, where Mr. Todd Chappell will present on RNA editing therapies [6]. Communication Strategy - The company plans to utilize its Investor Relations website, LinkedIn, and X (Twitter) for disclosing material nonpublic information and fulfilling its disclosure obligations under Regulation FD. Investors are encouraged to monitor these platforms for updates [8].